Why the study?
What is the rate of systemic thrombolysis use and fatality in pregnant women with pulmonary embolism?
What is the rate of systemic thrombolysis use and fatality in pregnant women with pulmonary embolism?
Systemic thrombolysis is used in approximately one third of pregnant women with pulmonary embolism and hemodynamic failure, highlighting a critical need for improved management strategies in this high-risk population.
Usage signals caution amid weak evidence against benefit; leaves open pregnancy-specific trials.
Pulmonary embolism-related fatality remains substantial in pregnant women with pulmonary embolism and represents a frequent cause of maternal mortality. The use of systemic thrombolysis was reported in one third of pregnant women with pulmonary embolism and haemodynamic failure. Better preventive and management strategies should be urgently implemented in this vulnerable patient group.
No takes yet. Share an insight, caveat, or question.
Hobohm et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: